share_log

新興市場銘柄ダイジェスト:リグアは大幅に反落、PRISMBioがストップ高

Emerging Market Stock Digest: Rigua fell sharply, while PRISM Bio hit the limit up.

Fisco Japan ·  Jul 3 02:25

<7090> Ligua 1980 -410

A sharp decline. A temporary stop was added in the morning, but after that, it was pushed by profit-making sales and turned negative compared to the previous day. The day before, Ligua announced that the new integrated functional mineral crystal (IFMC.) product “SLEEPINSTANT” developed by the company was introduced to all guest rooms (784 beds in total) at the Kansai Airport Washington Hotel (Izumisano-shi, Osaka), and investment funds were flowing in. It is said that IFMC can be expected to have a blood circulation promotion effect due to vasodilation by bringing it close to the body.

<6027> LawyerCom 3675 +405

Continued significant growth. Tokai Tokyo Intelligence Lab has begun new coverage with the rating “Outperform” and a target stock price of 6200 yen (closing price the day before 3270 yen). After evaluating it as “expecting to monetize products equipped with generative AI,” etc., it indicates that operating profit forecasts are 1,764 billion yen (company plan is 1.70 billion yen) for the fiscal year ending 25/3, 2,786 billion yen for the fiscal year ending 26/3, and 3.841 billion yen for the fiscal year ending 27/3.

<206A> PrismBio 669 +100

The stop was high, it was newly listed the day before, and purchases flooded in even after the initial price was set at 489 yen, which is higher than the public price (450 yen). We are involved in the drug discovery business, and in addition to having license out agreements with Eisai <4523> and Ohara Pharmaceutical (Chuo-ku, Tokyo) in our in-house development business, we have partnered with Ono Pharmaceutical Industry <4528> etc. in joint development projects. The operating profit and loss forecast for the fiscal year ending 24/9 is 888 million yen (previous fiscal year record deficit of 496 million yen), but sales are expected to expand to 300 million yen, up 267.8% from the previous fiscal year.

<5027> AnyMind 1166 +75

Continued significant growth. The main questions asked by investors in the 2nd quarter of '24 and their answers are disclosed. Among them, it was stated that “as the company as a whole grows, there is a possibility that the scale of M&A will gradually increase in the future,” and then “I would like to gradually increase the number of M&A cases per year,” and it has become a source of buyers. Also, it seems that it was revealed that gross profit for the first quarter of the D2C/EC business excluding contributions from DDI, which was acquired last year, increased 65% from the same period last year.

<2983> R Planner 1036 +150

The stop is high. The operating profit forecast for the fiscal year ending 25/1 has been revised upward from the previous 850 million yen to 1,180 billion yen (previous fiscal year results 532 million yen). In addition to the increase in the number of detached houses sold, gross profit has improved due to optimization of sales prices and price drops for some construction materials. At the same time, the year-end dividend forecast has been increased and revised from the previous 10.00 yen to 15.00 yen (10.00 yen for the previous fiscal year end results). It's 30.00 yen per year (15.00 yen in the first quarter).

<4268> Edge Technology 606 +28

Significantly higher. It is assumed that digital human resource development for government offices and local governments through AI education services is being strengthened, and public offering projects that received orders or announcements in fiscal year 24 have been clarified. In addition to local governments such as ICT job specialized training (basic) in Tokyo and in-house advanced AI human resource development courses in Shizuoka prefecture, it is said that they have received orders for AI basic training from the Defense Equipment Agency. It is said that by incorporating unique proposals aimed at solving issues faced by government offices and local governments through data utilization, it led to project orders.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment